Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MGTX
BuyPremium GrowerMeiraGTx Holdings plc · Healthcare · United States · $1.3B · Avg Vol: $8M/d
COMPANY DESCRIPTION
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing and commercializing novel treatments for inherited diseases, with programs in ophthalmology, salivary gland disorders, and Parkinson's disease. The company differentiates itself with its proprietary gene therapy platforms and a vertically integrated approach, including its own GMP manufacturing facility. This strategic integration supports control over its development pipeline for high-unmet-need indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.7M | 15.9M | 14.0M | 33.3M | 81.4M | 21.2% | 397.5M | 337.5M | 67.5M | -8.9% |
| EPS | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 | — | 0.87 | 0.51 | -1.39 | — |
| Shares | 44.5M | 48.5M | 63.6M | 78.4M | 81.1M | +82.1% | 96.0M | — | — | — |
| Debt | 23.7M | 92.2M | 89.3M | 84.8M | 88.7M | 39.0% | 112.3M | — | — | — |
| Equity | 185.4M | 117.7M | 138.2M | 67.8M | -5.8M | -28.5% | — | — | — | — |
| Op CF | -10.5M | -73.1M | -105.4M | -104.5M | -46.4M | — | 13.7M | — | — | — |
| Inv CF | -61.7M | -45.0M | 34.0M | 23.5M | -4.1M | — | — | — | — | — |
| Fin CF | 1.7M | 95.2M | 84.0M | 54.5M | 12.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc(you) | $1.3B | 68 | Buy |
| FTRE | Fortrea Holdings Inc. | $1.8B | 60 | Hold |
| TBPH | Theravance Biopharma, Inc. | $885M | 76 | Buy |
| MDXG | MiMedx Group, Inc. | $656M | 73 | Buy |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%